Immunotherapy aims to block the interaction between PD-1 on T cells and its ligand PD-L1 on tumor cell or alternatively, blocking the interaction between CTLA-4 on T cells and its co-stimulatory receptors CD80, CD88 or B7 on antigen presenting cells. The gene discussed is CTLA4; the disease is neoplasm.